DAVIS, Calif., June 3, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations and DSM Food Specialties announced they have signed a collaborative agreement involving early stage research of several biological active ingredients. Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), is a leading global provider of bio-based pest management and plant health products and DSM Food Specialties B.V. (DSM) is a Netherlands-based manufacturer of specialty ingredients for international food and beverage industries.
The agreement's goal is to unlock the full potential of biological active ingredients to improve the critical end points — crop production and food safety — of the food supply chain. MBI and DSM will exchange microorganisms from their libraries in order for their respective research teams to screen for biological activity in their specific areas of interest. For DSM, its area of interest is applications for its food ingredients business and for MBI, its interest is in crop protection and plant health areas.
"This agreement takes advantage of each company's strength in its core competencies. DSM Food Specialties is a world leader in fermentation and enzyme technology and is the ideal partner for exploring new applications of microbial strains for food safety and other food ingredient applications," states Dr. Alison Stewart, MBI Sr. VP of Research & Development and Chief Technology Officer. She adds, "Conversely, MBI has an industry-leading screening and development process to identify and commercialize candidates for crop protection and plant health applications. I believe we can expect viable development candidates to emerge from our collective research."
Ruth Donners, Innovation Manager, Food and Crop Protection for DSM, comments on the agreement, "This is a great example of how new advances in research can be maximized through collaboration. Both DSM and MBI have focused sets of skills that will be utilized in finding new applications for active ingredients the companies may not have accessed otherwise. Each of our teams conducting the research in which they specialize will give us the best opportunity for success."
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (Nasdaq:MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements relating to research results. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements, including the difficulty in predicting the outcome of product research and development efforts and regulatory approvals. Additional relevant information concerning risks can be found in the in the Form 10-K that the Company filed with the Securities and Exchange Commission on March 25, 2014.
Source:Marrone Bio Innovations